Endometrial cancer
- PMID: 26354523
- DOI: 10.1016/S0140-6736(15)00130-0
Endometrial cancer
Abstract
Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches (laparoscopic or robotic). Lymph node surgical strategy is contingent on histological factors (subtype, tumour grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients' characteristics (age and comorbidities), and national and international guidelines. Adjuvant treatment is tailored according to histology and stage. Various classifications are used to assess the risks of recurrence and to determine optimum postoperative management. 5 year overall survival ranges from 74% to 91% in patients without metastatic disease. Trials are ongoing in patients at high risk of recurrence (including chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities that best balance optimisation of survival with the lowest adverse effects on quality of life.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer.Int J Gynecol Cancer. 2015 Jan;25(1):75-80. doi: 10.1097/IGC.0000000000000306. Int J Gynecol Cancer. 2015. PMID: 25356534
-
An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.Anticancer Res. 2000 May-Jun;20(3B):1977-84. Anticancer Res. 2000. PMID: 10928137
-
Carcinoma of the endometrium.Drugs. 2001;61(10):1395-405. doi: 10.2165/00003495-200161100-00003. Drugs. 2001. PMID: 11558829 Review.
-
Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.Arch Gynecol Obstet. 2012 Nov;286(5):1269-76. doi: 10.1007/s00404-012-2431-2. Epub 2012 Jun 24. Arch Gynecol Obstet. 2012. PMID: 22729137
-
Current treatment options for endometrial cancer.Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89. doi: 10.1586/14737140.4.4.679. Expert Rev Anticancer Ther. 2004. PMID: 15270671 Review.
Cited by
-
Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.Diagn Pathol. 2021 Apr 8;16(1):28. doi: 10.1186/s13000-021-01093-4. Diagn Pathol. 2021. PMID: 33832498 Free PMC article.
-
FBXO17 Inhibits the Wnt/β-Catenin Pathway and Proliferation of Ishikawa Cells.Int J Med Sci. 2022 Aug 15;19(9):1430-1441. doi: 10.7150/ijms.60335. eCollection 2022. Int J Med Sci. 2022. PMID: 36035375 Free PMC article.
-
Insulin Resistance and Endometrial Cancer: Emerging Role for microRNA.Cancers (Basel). 2020 Sep 8;12(9):2559. doi: 10.3390/cancers12092559. Cancers (Basel). 2020. PMID: 32911852 Free PMC article. Review.
-
LncRNA RP11-395G23.3 suppresses the endometrial cancer progression via regulating microRNA-205-5p/PTEN axis.Am J Transl Res. 2020 Aug 15;12(8):4422-4433. eCollection 2020. Am J Transl Res. 2020. PMID: 32913516 Free PMC article.
-
Construction of miRNA-mRNA Regulatory Network and Prognostic Signature in Endometrial Cancer.Onco Targets Ther. 2021 Apr 6;14:2363-2378. doi: 10.2147/OTT.S272222. eCollection 2021. Onco Targets Ther. 2021. PMID: 33854334 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources